609785-70-8

Basic information

• Product Name: Carbamic acid, (4-cyano-3-methoxyphenyl)-, 1,1-dimethylethyl ester
• CAS NO: 609785-70-8
• Molecular Formula: C13H16N2O3
• Molecular Weight: 248.282
• Mol File: 609785-70-8.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (4-cyano-3-methoxyphenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (4-cyano-3-methoxyphenyl)-, 1,1-dimethylethyl ester(609785-70-8)
• EPA Substance Registry System: Carbamic acid, (4-cyano-3-methoxyphenyl)-, 1,1-dimethylethyl ester(609785-70-8)

Safety Data

• Hazardous Substances Data: 609785-70-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7251-09-4 4-amino-2-methoxybenzonitrile 
• 28163-00-0 4-nitro-2-chlorobenzonitrile 

Downstream Products

• 609785-73-1 tert-butyl 2-[benzyl(methyl)-amino]ethyl(4-cyano-3-methoxyphenyl)carbamate 
• 398487-31-5 4-chloro-7-methoxyquinoline-6-carbonitrile 
• 417716-92-8 lenvatinib 

Relevant articles and documents

Preparation method of lenvatinib

The invention discloses a preparation method of lenvatinib, which comprises the following steps: by using 4-nitro-2-chlorobenzonitrile as an initial raw material, introducing nitro into molecules forelectron withdrawing, thereby greatly lowering the elect

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.